We show that human osteosarcoma cells (Saos-2) have downregulation of a3b1-integrin compared to normal bone cells; this was further described in human osteosarcomas and in a primary murine sarcoma. The a3 gene was silenced in Saos-2 cells causing a low expression of a3b1-integrin and reduction in collagen attachment with increasing migratory capacity. Chromatin immunoprecipitation assay performed on a3 promoter established that Myc and Yin Yang protein (YY1) cooperate in tandem to downregulate the a3 gene. This silencing mechanism involves the binding of Myc and YY1 to DNA and formation of complexes among Myc/Max, YY1, CREBbinding protein and deacetylation activity. The promoter containing deletions of E-boxes or YY1 cassettes failed to downregulate the transcription of a reporter gene as well as the inhibition of deacetylation activity. Overexpression of both Myc and YY1 was necessary to determine the a3-integrin promoter downregulation in normal osteoblasts. This downregulation of a3b1-integrin can contribute to the acquisition of a more aggressive phenotype. YY1 regulated negatively the Myc activity through a direct interaction with the Myc/Max and deacetylase complexes. This represents a novel silencing mechanism with broad implications in the transcription machinery of tumours.
Introduction
Integrins are heterodimeric cell surface glycoprotein receptors composed of a and b subunits, which pair in a variety of ways to form at least 22 integrin complexes (Hynes, 2002) . The expression of some integrin receptors is cell line specific, whereas other integrins are found on a wide range of cells. Physiological expression of specific integrin patterns is frequently altered in transforming or tumour cells (Schwartz et al., 1995; Parise et al., 2000) . However, molecular mechanisms explaining this event are still unknown. As well described, Myc protein is a pivotal transcription factor regulating several genes involved in differentiation and oncogenic transformation (Pulverer et al., 1994; Dang and Lewis, 1997; Napoli et al., 2002; de Nigris et al., 2003) . Some studies demonstrated that Myc regulates the transcription level of the Yin Yang protein (YY1) and, in turn, YY1 itself is involved in Myc gene regulation (Riggs et al., 1993; Lee et al., 1994; Napoli et al., 2002; de Nigris et al., 2003) . However, transcriptional cooperation between Myc and YY1 would be expected, but is not yet established in transformed cells. YY1 is a ubiquitous zinc-finger transcriptional factor (Galvin and Shi, 1997; Thomas and Seto, 1999) known to either repress or activate several transcriptional factors, among which are c-fos, b-casein, a-actin, histon H4, interferon-g, interleukin-adenoassociated virus P5 promoter, human papilloma virus type 16 and 18, Moulonei leukaemia virus and several other cellular and viral genes (Flanagan et al., 1992; Shrivastava and Calame, 1994; Ye et al., 1996; Thomas and Seto, 1999) . YY1 binds to DNA through a specific consensus sequence interacting directly with histone deacetylase (HDAC) complexes and via CREB-binding protein (CBP) with acetylase (Davie and Chadee, 1998) . Nuclear HDACs induce nucleosomal core histone rearrangement promoting a lock chromatin with gene silencing (Workman and Kingston, 1998) .
Osteosarcoma is one of the most common primary bone tumours in children and adolescents with very low patient survival (Arndt and Crist, 1999) . To date, the exact molecular mechanisms involved in the pathogenesis of osteosarcoma have been poorly studied. In the present study, we investigated basic regulatory mechanisms involving a3b1-integrin in osteosarcoma in comparison to normal osteoblasts. We cloned and characterized the human regulative region of a3 gene, and clarified the cooperative role among Myc, YY1 and deacetylase in the silencing of the a3 promoter.
Results

a3b1-Integrin expression
First, the a3b1-integrin expression level in osteosarcoma cell line (Saos-2) was investigated and the mRNA was processed by reverse transcription-polymerase chain reaction (RT-PCR) (glyceraldehyde-3-phosphate dehydrogenase was used as control for amplification efficacy). As shown in Figure 1a , the level of a3-integrin mRNA in Saos-2 (lane 2) was four-fold lower than normal human osteoblastic cells (Ost) (lane 1). Very little difference was observed for the other a subunits expressed as densitometric analysis. The b subunits were almost present; however, difference in the expression level among the different b subunits was detected in Saos-2 compared to Ost cells (Figure 1b) . Immunoprecipitation (IP) experiments were performed to identify which subunit b interacts with a3-integrin. The total protein extract from Saos-2 cells was immunoprecipitated with a panel of monoclonal antibodies recognizing the b1, b3, b4 and b5 subunits and then subjected to Western blot analysis for a3; a very low signal for a3-integrin protein was detected only in IP performed with anti-b1 antibodies ( Figure 1c) . As a control, total protein extracts were immunoprecipitated with a3 and revealed for b1-integrin; no signal was obtained with the other a subunits. Also in this case, only the a3 antibodies immunoprecipitated the b1 subunit, confirming the result that the a3-integrin binds preferentially to b1 subunit in Saos-2 cells. The a3 subunit binds b1, b4 and b5 subunits in osteoblastic cells. The relative level of a3b1-integrin expression on cell surface was analysed by fluorescent analysed cell sorter (FACS) scan using antib1 antibodies (Figure 1d and e). We obtained a little positive signal (less than 1%) with the b1 antibody subunit compared to normal cells (Figure 1d ), and the same result was obtained also with the a3 antibody. Immunofluorescence experiments performed on living Saos-2 cells, by using anti-b1 and -a3 antibodies, confirmed that the a3b1-integrin was almost absent on Saos-2 cells surface ( Figure 1f ). The very low expression of a3b1-integrin on Saos-2 cells documented by FACS   α1   α1  α2  α3  α4  α5  β1  β2  β3  β4  β5   α2  α3  α4  α5  β1   β1   β1   β1   IP: WB:α3 and immunofluorescence compared to osteoblastic cells suggests that transcriptional downregulation of a3 subunit contributes to a significant reduction of a3b1 expression on Saos-2 cell surface. However, the difference in amount of a3b1 exposed on cell surface between Saos-2 and Ost cells suggests that other post-transcriptional mechanism could be involved.
Saos-2 show decreased attachment to collagen I and laminin To investigate whether the downregulation of human a3b1-integrin promotes alterations on morphology and cell-cell interactions, the a3-integrin subunit was overexpressed in Saos-2 cells. The full length of human a3-integrin cDNA was cloned in a pCMVFlag vector obtaining the construct pCMVFlag-a3 (see Materials and methods). By using this construct, we stably transfected and selected several Saos-2 clones overexpressing the human a3 gene detected by Western blot by using the Flag-tag antibody (Figure 2a ). The Saos-2 clones overexpressing a3-integrin (Saos-2/Flaga3), detected also by immunofluorescence using flag antibody (Figure 2b ), exhibited an increase of b1 protein on cell surface together with altered morphology compared to control (Saos-2pCMV). These data suggest that ectopic overexpression of a3 in Saos-2 could be sufficient to restore partially the expression of a3b1 on cell surface. Then, we evaluated the effects on the attachment to b1 ligand such as collagen I and laminin. Saos-2 cells and two independent Saos-2/Flag-a3 clones were plated onto collagen I-and laminin-treated plates, as described in Materials and methods. As shown in Figure 2c , Saos-2 cells exhibited a significant decrease in attachment to collagen I-treated plates compared to cells overexpressing a3 protein (Saos-2/Flag-a3). To investigate whether downregulation of a3b1-integrin might lead to acquisition of a more migratory and/or metastatic phenotype, we evaluated cell migration on collagen I and laminin. By using migratory chamber assays, we measured the migratory capacity of Saos-2 and Saos-2/Flag-a3 on a collagen I or laminin concentration gradient using 2% fetal bovine serum (FBS) as a chemoattractant. Saos-2 cells were more migratory on a collagen I concentration gradient than Saos-2/Flag-a3 cells (Po0.05; Figure 2d ). In contrast, laminin did not support cell migration in any of the cell lines tested.
Regulative elements of the a3 gene To understand the mechanism of a3-integrin transcription repression, we isolated the promoter region of the human a3 gene. To clone the promoter region of the human a3 gene, a polymerase chain reaction (PCR)-based method was utilized (see Materials and methods). Approximately, 0.8 kb of the 5 0 -flanking region was cloned into a promoterless pGL3-basic vector to give a pGL3-a3p construct, and then sequenced ( Figure 3a) . The sequence analysis performed by the ProScan program revealed a high homology with mouse a3 promoter around 80% (Figure 3b ). The human a3 promoter was TATA less, like the mouse one. The nucleotide sequence of a3 promoter reported in the present study has been deposited in the GenbanK database with accession number DQ394293. Several potential transcription elements were identified by the MatInspector v2.2 program (core similarity 0.8, matrix similarity 0.9) using TRANSFACT matrices (Figure 3a) . These elements included the potential binding site for ETS, c-Myc, Sp1, nuclear factor-kB, GC sequences and a peculiar two binding sites for YY1 each followed by two E boxes (Figure 3a) . To evaluate the promoter activity of this construct, Saos-2 and normal cells were transiently transfected with the full-length and with serial-deleted constructs of pGL3-a3p (Figure 4a ). The promoter activity was expressed as a ratio relative to a promoterless construct and normalized with the empty vector for renilla activity. The full-length construct pGL3-a3 (Luc1) had a four-fold less luciferase activity in Saos-2 than in normal cells (Figure 4b ). Deletions of both potential binding sites for YY1 (Luc3 construct) showed an increase of two-fold in the luciferase activity compared to full-length construct (Luc1) in Saos-2 cells (Po0.05; Figure 4b ). In contrast in normal cells, deletions of YY1-binding site do not influence the promoter activity, whereas the deletion of Ets site (Luc5) reduced drastically the luciferase activity ( Figure 4b ). These results suggest that the promoter works differently in normal than in osteosarcoma cells. In normal cells, the Ets-binding site regulates positively a3 promoter, whereas the other binding site does not influence the promoter activity. In contrast, the YY1 and E box regulate negatively the a3 promoter activity only in Saos-2 cells. We verified the expression level of YY1 and Myc proteins by Western blot. This revealed the accumulation of c-Myc, Max and YY1 proteins in Saos-2 cells but not in normal cells (Figure 4c ).
YY1-binding site in vitro
To establish whether the overexpression of YY1 was linked to downregulation of a3 subunit of integrin a3b1, we studied in detail the two potential YY1-binding sites at positions À687 and À586 of the 5 0 -flanking region of human a3 gene (Figure 3b ). To analyse the bind of YY1 to these sites, shift assays were carried out in the presence of the corresponding DNA probe and two mutant sequences with Saos-2 nuclear extracts ( Figure 5a ). The binding shift experiment in which the oligonucleotides À687 and À586 shifted in the presence of a nuclear extract from Saos-2 cells. The introduction of mutations on the corresponding YY1 core motifs present in positions À687 and À586 (see methods) determined the disruption of the complex indicated by the arrow. The formation of these complexes was again retarded by the antibody against YY1. Electrophoretic mobility shift assay (EMSA) competition experiments were carried out in order to confirm the affinity of YY1 to the binding site. In Figure 5b , the YY1 P32-labelled probes were incubated with nuclear extracts in the presence of 50-and 100-fold excess of unlabelled probe. The amount of 100-fold excess of unlabelled probe completely compete for the formation of the YY1 complexes. No competition was observed with 100-fold excess of mutant oligonucleotides ( Figure 5c ). Figure 5d shows the Western blot performed on the same gel retardation assay (performed in Figure 5a ) by using the polyclonal anti-YY1 antibody raised against the entire protein. A protein containing YY1 was formed with oligonucleotides À687 and À586 and no signal was obtained with the two mutant oligonucleotides.
YY1 binds the a3 promoter in vivo by chromatin immunoprecipitation assay Chromatin immunoprecipitation assay (ChiP) was performed to evaluate whether YY1 binds the a3 promoter in vivo. Genomic DNA was immunoprecipitated with anti-YY1 antibodies and amplified with primers in a3 promoter spanning from À700 to À454 of the a3 gene. As control, the same fraction was immunoprecipitated with antibodies directed against SP1 and immunoglobulin G (IgG). The a3 promoter was immunoprecipitated in the presence of anti-YY1 antibodies demonstrating that YY1 binds in vivo the a3 promoter ( Figure 6a ). We observed a strong signal corresponding to the a3 promoter immunoprecipitated with SP1 antibodies. By using the ChiP assay through antibodies recognizing proteins known to bind the a3 promoter (sequence analysis), we have identified protein interactions on a3 promoter. As shown in Figure 6a , genomic DNA was immunoprecipitated with Myc, Max, HDAC3, HDAC2, CBP, SP1 and YY1, and amplified with primers for the a3 promoter. As shown in Figure 6a , we observed the presence of the transcription factors Myc and Max, the coactivator molecule CBP and the histone deacetylation HDAC2; YY1 did not bind the promoter region spanning from À404 to À239 (as expected by the sequence analysis) (Figure 6b ). To verify which protein interacts directly with YY1 protein, soluble chromatin derived from Saos-2 was immunoprecipitated with c-Myc, Max, CBP and YY1 (first IP) ( Figure 6c) ; after release, one aliquot was used for PCR amplification, and the other was again immunoprecipitated with YY1, Myc and Max antibodies (II IP), respectively (Figure 6c ). The PCR was also performed on the unbound supernatant fraction obtained from the second IP (Figure 6c ), revealing that YY1 binds directly Max and CBP, whereas the interaction between YY1 and Myc was Cellular mechanisms of neurobiology, immunology and human disease F de Nigris et al mediated by CBP on a3 promoter in vivo. IP experiments performed on total protein extracts from Saos-2 confirmed that Max binds YY1, the YY1 binds CBP and CBP binds Myc, whereas a very faint signal was observed when YY1 immunocomplex was revealed for Myc ( Figure 6d ). In order to clarify the protein interaction on the a3 promoter, we transfected cells with siRNACBP and siRNAYY1 and performed the ChiP assay on the a3 promoter after 48 h (Figure 6e and f). Results indicated that CBP was not present on the promoter in the presence of siRNACBP (Figure 6e ). The ChiP assay positive for Myc was reimmunoprecipitated (second IP) with YY1 and Max, revealing that Myc did not bind YY1 (and vice versa), whereas Max bound YY1 (Figure 6e ). Moreover, the ChiP assay performed on cells transfected with siRNA for YY1 revealed that in the absence of YY1 protein, CBP did not bind the a3 promoter ( Figure 6f ). Figure 6g illustrates a possible model of transcription complex assembly at the present state of knowledge.
YY1 and c-Myc cooperate to downregulate the transcription activity of the a3 promoter through the acetylation of YY1 To assess the role of YY1 during the regulation of the transcriptional activity of the a3 promoter, we stably transfected normal osteoblastic cells with pCMVHisMyc, pCMVFlagYY1 and both vectors in which the full length of Myc, or YY1 were cloned, and selected six clones for each transformation (Figure 7a ). The clones double transfected with pCMVHisMyc, pCMVFlag-YY1 had lower level of a3-integrin protein compared to single transfection (Figure 7a ). The clones, overexpressing YY1, c-Myc or both, were transiently transfected with luciferase reporter plasmid pGL3 in which the a3 promoter spanning from À705 to À110 was cloned (pGL3-a3p). Osteoblastic cells overexpressing c-Myc or YY1 cDNA did not show any significant difference in promoter activity (Figure 7b) . A strong reduction (fivefold) of the a3 promoter activity was assayed in cells stably overexpressing both Myc and YY1 proteins. Thus, the downregulation of a3 protein was dependent on overexpression of both protein YY1 and Myc. To understand whether the effect of YY1 on a3 promoter was dependent on direct interaction of Myc to promoter, it was mutated (by site direct mutagenesis) in all E boxes present on the promoter obtaining the construct pGL3-a3pDMyc. Ost clones overexpressing Myc, YY1 or both c-Myc and YY1 proteins were transfected with pGL3-a3p ( Figure 7b ) and pGL3-a3-DMyc (Figure 7c Cellular mechanisms of neurobiology, immunology and human disease F de Nigris et al transfected with pGL3-a3-DMyc compared to wild-type promoter (lane 9 compared to lane 5 in Figure 7c ). The same results were obtained in Saos-2 cells overexpressing constitutively Myc and YY1 proteins. The a3 promoter deleted in E boxes (pGL3-a3-DMyc) or in YY1-binding sites (pGL3-a3-Dyy1) showed an increase of luciferase activity compared to wild type (lanes 3 and 2 compared to lane 1 Figure 7d) . Therefore, the downregulation of YY1 was closely linked to the presence of both YY1 and Myc proteins and their binding sites. The activity of YY1 is known to be regulated through acetylation by p300 and deacetylation activity by HDACs. To study whether the repressive effect of YY1 upon the a3 promoter was dependent on HDAC activity, we used trichostatin A (TSA), which is a specific inhibitor of HDACs. Saos-2 cells were transfected with pGL3-a3p full-length construct in the presence or absence of TSA (Figure 7e ). The repression of the a3 promoter was 10-fold reduced in the presence of TSA. The TSA had no effect on Saos-2 cells transfected with pGL3-a3-DYY1 construct lacking the YY1-binding sites (Figure 7e ). These data indicate that the binding site for YY1 and c-Myc cooperate in tandem to determine downregulation of the a3 promoter that is b1-integrin expression level in mouse model of osteosarcoma and in human tumour biopsies To have an immediate relevance for a part of our findings in the context of cancer malignancy in vivo, we evaluated the expression level of b1-integrin. Immunohistochemical analysis was performed on sections of mouse bone primary tumours (obtained from nude mice injected with 1 Â 10 6 Saos-2 cells). As shown in Figure  8a -d, the b1-integrin staining was strong in normal bone tissue ( Figure 8b) ; when the degree of malignancy was progressively lost, the majority of cells in tumour area was negative for b1-integrin immunostaining. Similar data were obtained in human tumour biopsies from femoral osteosarcoma (Figure 8e-h) . The immunohistochemistry showed that in comparison to normal bone, (Figure 8f ) differentiated osteosarcoma with high spindle cells with low osteoid matrix ( Figure 8g ) had a strong staining for b1-integrin. In undifferentiated osteosarcomas, showing the highest osteoid matrix deposition and hole in the tissue (Figure 8h ), the b1-integrin was significantly reduced. Data were dependent also on calcification of paraffin-embedded sections and showing colocalization of Myc and YY1 in Cellular mechanisms of neurobiology, immunology and human disease F de Nigris et al osteosarcoma tissues (data not shown). Therefore, the observed a3-integrin downregulation seen in cultured cells was also present to some degree in osteosarcoma tissues. Obviously, further immunohistochemistry experiments are needed to better characterize all signalling pathways investigated in the present study.
Discussion
We show that a3b1-integrin (but not other a and b subunits) is downregulated (because a3 is selectively transcriptionally silenced) in human osteosarcoma cells.
This was observed to some degree also in human osteosarcoma biopsies and in a primary murine osteosarcoma tumour. In osteosarcoma cells, a3b1 downregulation determined alterations in cell morphology, reduction in collagen attachment and increase in cell motility. These characteristics contribute to the acquisition of a more aggressive phenotype of tumour progression. The a3b1 downregulation is not a general event of cancer cells. Cellular mechanisms of neurobiology, immunology and human disease F de Nigris et al b1-, a2-and a3-integrin subunits was observed in mammary carcinomas (Pignatelli et al., 1991) . However, b1-integrin-blocking antibodies induced a morphological and functional reversion of tumoral phenotype (Weaver et al., 1997) and blocked the proliferation (Wang et al., 2002) in breast cancer cells. In vulva squamous carcinomas, b1-integrin is overexpressed and required for the invasive pattern (Brockbank et al., 2005) . Interestingly, post-transcriptional modification of b1-integrin contributes to colon cancer progression (Seales et al., 2005) . Mechanisms underlying modified integrin expression are still unclear, and possibly involve some oncogenes (Schwartz, 1993) . A single relationship was established between Myc overexpression in neuroblastoma cells with reduced b1-integrin levels (Judware and Culp, 1995) . Moreover, in an early study, ectopic overexpression of Myc protein determined a reduction of integrins in tumour cells compared to untransfected tumour cells (Judware and Culp, 1997) . Regulatory elements of human a3-integrin promoter and the exact mechanism of integrin a3b1 downregulation were also investigated. We cloned the regulatory element of a3 gene and demonstrated that both YY1 and Myc proteins, naturally overexpressed in osteosarcoma cells, cooperate to downregulate its expression. We demonstrated that the proximal 5 0 -flanking region of the human gene show 80% sequences identical to the mouse gene, including most potential binding sites and contain a peculiar presence of one YY1 and two E boxes in tandem repeat. The knockout of the YY1 is lethal, demonstrating an essential function of this protein during the development of the mouse embryo (Donohoe et al., 1999) . This element is sufficient to regulate positively the transcription in normal cells and negatively in osteosarcoma cells. There are several possible mechanisms of the negative action of YY1 (Gordon et al., 2006) . It can block the transcription through the interaction with transcription factors masking their activation domain or recruitment of corepressor molecules or, finally, by modifying histones to induce a close chromatin state (Hynes, 2002) . We demonstrated by EMSA that YY1 and Myc proteins bind their target sequences on the a3 promoter. By IP first, and then by direct ChiP assay, we established that YY1 binds directly Max or, by using CBP, the Myc protein. We provided convincing evidence that HDACs complex binds the a3 promoter playing a pivotal role as negative regulator of transcription in transformed cells; thus, the block of deacetylation activity failed the capacity to repress the a3 promoter. Deletion of YY1 cassettes or E boxes on a3 promoter suppresses the downregulation of a3 promoter in Saos-2 cells. Finally, we demonstrated that overexpression of both Myc and YY1 proteins in normal bone cells is necessary and sufficient to determine a downregulation of the a3 promoter. From our findings, we proposed a model of a3 promoter regulation (Figure 6f ). We have hypothesized that high cellular content of YY1 and Myc determine the interaction of these proteins to their target sequences on the a3 promoter, then the deacetylation of YY1 protein can modify the DNA structure locking the chromatin in a close status responsible for the a3 gene silencing. The direct biological implication of integrin a3b1 on the surface of transformed cells increased migratory capacity of these cells contributing to the acquisition of malignant phenotype and may represent a novel therapeutic target.
Materials and methods
Plasmids construct
The Myc cDNA was a gift from Dr GL Condorelli . The YY1 full-length cDNA was obtained by RT-PCR on Saos-2 polyA mRNA (Oligotex mRNA Kit Qiagen, Hilden, Germany) using the following primers: forward, Cellular mechanisms of neurobiology, immunology and human disease F de Nigris et al and reverse, 5 0 -TCCGCCTCGAGTCACTGGTTGTGTTT TTGGCCT-3 0 ; both cDNAs were subcloned in NcoI/XhoI restriction sites of pCMVFLAG expression plasmid from (Stratagene, Milan, Italy) . The a3 human cDNA was obtained by PCRs on human osteoblastic polyA mRNA using the following primers respectively: forward, 5 0 -GCGGCCGC ATGGGCCCCGGCCCCAGCCG-3 0 -74; reverse, 5 0 -GGTA CCCTGGGCACCAAGGTCTTGTG-3 0 -1500; forward, 5 0 -GGTACCGCCAGCTGTGCTGGACCCTG-3 0 -1501 and reverse, 5 0 -TCAGTAGTCGTCGGTCAGCCCTCGAG-3 0 -3229. The right sequences were confirmed by direct sequencing. The DNA constructs were purified using Qiagen methods. The mutant constructs of the a3 promoter were obtained with GeneEditor in vitro site-direct mutagenesis system (Promega, Milan, Italy) using the primers, as indicated in cloning methods. The deletion constructs of a3 promoter were obtained by RT-PCR performed with primers following the conditions indicated in RT-PCR analysis paragraph.
Cell lines, transfections and treatment
Saos-2 and CRL-11372 (human osteoblasts) cells were obtained from the American Type Culture Collection. Saos-2 cells were cultured in Dulbecco's medium essential medium supplemented with 10% FBS, 5% glutamine and 1% penicillin-streptomycin. CRL-11372 cells were cultured in medium essential medium supplemented with 10% FBS, 5% glutamine and 1% penicillin-streptomycin. The transfections were carried out by Lipofectamine 2000 (Invitrogen, Milan, Italy) according to the manufacturer's recommendations. Briefly, 10 mg of plasmids DNA was used to transfected 10 mm plate containing 5 Â 10 5 cells. To select pFlag/YY1 and pCMVFlag-a3, geneticin at the concentration of 200 mg/ml was used for 4 weeks, to select pc4His-Myc clones, and 1 mg/ml Zeocin was used for 3 weeks. Several resistant clones were selected and assayed by anti-4His tag from Invitrogen and anti-Flag (Sigma Chemicon, Milan, Italy), the expression of exogenous genes. For co-transfection, experiments were transient transfected 10 mg of plasmids pGL3-basic containing the a3 promoter fragments in Saos-2 and in CRL-11372 cells and 1 mg of pRlCMV as internal control (Promega). After 48 h, luciferase and renilla activities were determined in duplicate samples, using the Dual luciferase detection kit according to the manufacturer's instructions (Promega). The data represent the mean7s.d. of three independent experiments. Saos-2 cells (10 5 ) were plated in triplicate on six multiwells in the presence or absence of TSA T8552 (Sigma, Milan, Italy) for 6 h before transfection at the concentration of 100 ng/ml.
Western and IP
Total protein extractions were prepared as described previously (Napoli et al., 2000; de Nigris et al., 2002) . For IP, 1 mg of protein lysates were incubated with specific antibodies for 1 h at 41C, and 30 ml of A/G plus sepharose beads were added (Santa Cruz, Milan, Italy) at 41C O/N. Immunocomplexes were eluted in loading buffer (Biorad, Milan, Italy) . Total protein extracts were resolved by sodium dodecyl sulphatepolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Millipore, Milan, Italy) 
RT-PCR analysis
Total RNAs were extracted using Total RNA Isolation System (Promega). Five micrograms of total RNA were reverse transcripted using the Reverse Transcription System (Promega). The PCR conditions for integrin amplifications were 951C 30 s, 551C 30 s, 721C 30 s (30 cycles) and 721C 5 min. For detection of integrins, the primers shown in Table 1 were used (Kawashima et al., 2001) . The Northern blot was performed by Maniathis procedures modified as described previously (de Nigris et al., 2001) . The conditions for YY1 and a3-integrin cDNA amplifications were: 951C 1 min, 551C 1 min and 681C 2 min (35 cycles), using Taq Platinum (Stratagene) in the presence of enhancer buffer 1 Â . The conditions for deletion constructs were: 951C 30 s, 551C 30 s, 721C 30 s (30 cycles) and 721C 5 min. Oligos were:
ChIP assay
The ChIP assays were performed essentially as described (Shang et al., 2000) . The IPs were performed with 15 mg of DNA by using one of the following antibodies: c-Myc (C-33 sc 42), CBP (A-22 sc 369), HDAC2 (H-99 sc 11417), Max (C-17 sc 197), Sp1 (H-225 sc 14027) and YY1 (C-20 sc 281) obtained from Santa Cruz Biotechnology. Eluates were pooled and heated at 651C for at least 6 h to reverse the crosslinking. DNA fragments were purified with a Qiaquick Spin Kit (Qiagen, CA, USA). For PCR, 50 ml DNA extraction and 40 cycles of amplification were used with following primers: a3 promoter forward À705, 5 0 -GGACGTCGGTTCCCAGATGC-3 0 and reverse À454, 5 0 -CTCCTCATCCTCCCTACCCC5 0 -3 0 ; and
0 . PCRs were performed under the following conditions: 951C 30 s, 551C 30 s, 721C 30 s (50 cycles) and 721C 5 min.
Electrophoretic mobility shift assay Nuclear extracts were prepared as described Gordon et al., 2006) . Protein concentration was determined by the Bradford method . The oligonucleotide sequences were used (see Table 1 ). EMSAs were carried out as described . The competition was performed using 10-, 50-and 100-fold molar of cold oligonucleotides. The supershift experiments were performed in the presence of YY1 antibodies (C20 sc 281). The resulting complex was resolved in a non-denaturing 5% acrylamide gel in 1 Â Tris borate ethylenediaminetetraaceticacid. Oligonucleotides for binding shift were: Gel retardation assays followed by Western blot Gel retardation as described above, except that 25 mg of nuclear extract and 5 pmol of DNA probe (instead of 0.05 pmol) were used. After migration, the gel was soaked in 50 mM Tris-HCl, 40 mM Gly, 1 mM SDS and 20% methanol for 30 min at room temperature before being submitted to Western blot with YY1 (H-414) from Santa Cruz.
Cloning and sequencing of the 5 0 -flanking region of the a3 gene To clone the 5 0 -flanking region of the a3 gene, a PCR-based method was utilized. Specific primers were designed from the 5 0 -end of the known a3 cDNA sequences from bioinformatic search in GenbanK. Saos-2 genomic DNA was isolated by QIAamp DNA (Qiagen) and served as a PCR template. The sequences of the primer set used in PCR amplification are described as follows: forward À710, 5 0 -GCCGCCGC GCACGGACGTCGG-3 0 ; reverse þ 1, 5 0 -CATGGCTGC CAGCGGAAGCGGG-3 0 , which introduce XhoI and HindIII sites. The PCR conditions are as follows: the first cycle, 941C for 2 min, 551C for 1 min and then 721C for 3 min; the second to 35th cycle, 941C for 40 s, 601C for 1 min and then 721C for 3 min, and final extension for 10 min at 721C. The amplified fragment of 710 kb was digested with XhoI/HindIII and cloned in pGL3-Basic (Promega). Homology searches were performed using BLAST (Basic local Alignment Search Tool) from the national Center for Biotechnology Information (NCBI) at http://www.ncbi.nlm.nih.gov. Putative transcription factor binding elements were analysed using the program SignalScan by Genomatix MATINSPECTOR (http://thr.cit.nih.gov/ molbio/signal/ and http://www.genomatix.de/products/index/ html.
Primers used for deletion of the a3 promoter were: Target deletion Luc1: positions À653 and À110, primer sequences -5 0 -GGCTGGCCTTTTCAGCAGCA-3 0 and 5 0 -TGCGTCTCGGATCCCTTCCTAA; target deletion Luc2: positions À555 and À110, primer sequences -5 0 -GGAGGGA AATCTAAGCCTTTGGG-3 0 and 5 0 -TGCGTCTCGGATC CCTTCCTAA; target deletion Luc3: positions À710 and À404, primer sequences -5 0 -GCCGCCGCGCACGGACGTC GG-3 0 ; target deletion Luc4: positions À710,À604, primer sequences -5 0 -GCCGCCGCGCACGGACGTCGG-3 0 and 5 0 -GGATTTGYCTGGCCGCTTTCC-3 and target deletion Luc5: À404À239, primer sequences -5 0 -CTTTCCCCGG AAGGAAAGC-3 0 and 5 0 -CAGCGGAAGCTAGGGCCG AA-3 0 .
Collagen and laminin attachment assays Saos-2 cells were disengaged from culture flasks with nonenzymatic Cell Stripper solution (Cellgro, Herndon, VA, USA), and then resuspended in serum-free medium. Cells were plated onto tissue culture-treated dishes precoated with either 20 mg/ml of basement membrane laminin isolated from Engelbreth-Holm-Swarm murine sarcoma cells (Sigma) or 30 mg/ml of bovine collagen (Cohesion, Vancouver, British Columbia, Canada), and blocked with 2% denatured bovine serum albumin (BSA). Cells were also plated onto dishes coated with 2% denatured BSA alone to check for nonspecific binding. After 30 min of incubation at 371C, non-adherent cells were removed by phosphate-buffered saline (PBS) washing. Attachment was quantified by crystal violet staining as described (Arndt and Crist, 1999) . Collagen haptotaxis was evaluated using the QCM Collagen I Quantitative Cell Migration Assay Kit (Chemicon Int., Milan, Italy) following the manufacturer's instructions. For laminin haptotaxis assays, 6.5-mm-diameter Transwell migration chamber insert with 8.0 mm pore size PET membranes (Corning Acton, Milan, Italy) were coated on the underside with 20 mg/ml laminin overnight at 41C in PBS. The undersides of the chamber inserts were then overcoated with 1% denatured BSA. After washing with PBS, laminin haptotaxis was analysed using the conditions described above for collagen.
Fluorescent analysed cell sorter
The cell sorter was performed using 500 Â 10 3 stained with b1-integrin phycoerythrin antibody (CD20) from Santa Cruz, and analysed in a FACScan flow cytometer (Becton Dickinson, Flanklin Lakes, NJ, USA), as described Gordon et al., 2006) . Non-immune mouse IgG was used as the negative control.
Immunofluorescence Cells were grown on coverslips and transiently or stably transfected as above, then were fixed in paraformaldehyde for 5 min and stained with an anti-Flag (1:300). For b1 staining, 10 5 living cells were incubated in 10 ml of cold PBS in the presence of b1 (1:100) antibodies for 30 min, then washed two times with PBS and incubated with secondary antibodies as above. The secondary antibodies used were anti-rat Alexis 594 and anti-mouse Alexis 488 (1:800) (Molecular Probes). Preparations were viewed in a Leica confocal TCSS82 microscope and in a Zeiss microscope Axophoto.
In vivo experiment and microscopic examination Female athymic nu/nu mice, weighing 25-35 g (Harlan), were used. Animals were kept under pathogen-free conditions and were fed on a standard laboratory diet. The experimental protocols adhered to the rules outlined following Guidelines on the Protection of Experimental Animals by the council of the European Commission and local Animal Care committees. Saos-2 cells (5 Â 10 6 ) were xenografted under the skin of nude mice. Tumour size was monitored after 2 weeks. Volume was calculated from the average of tumour length and according to the formula 4/3pr 3 . The mice were killed when the tumour reached a size of >100 mm 3 . When tumour size was >100 mm 3 , mice were killed and tumours were dissected. Slides of 4% formalin-fixed and paraffin-embedded tumours from mice and from human biopsies (n ¼ 6) were routinely stained with haematoxylin-eosin and immunohistochemically for human b1-integrin with (CD 29) from Alexis, and b1 (Clone 7F10) DIAPATH for mouse immunohistochemistry.
Transfection with YY1 siRNA Transfections were performed using Lipofectamine 2000 reagent (Invitrogen life Technologies) and SureSilencing siRNA kit (Super Array Bioscience, New York, USA) according to the manufacturer's instructions. Briefly, 3 ml of YY1 siRNA or CBP siRNA, a negative control of siRNA solution, was incubated with 4 ml of the transfection reagent in optimum medium for 20 min to facilitate the complex formation. The resulting mixture was added to Saos-2 cells and cultured in six multiwells with 3 ml of medium.
Statistical analysis
All experiments were performed in triplicate and analysed by analysis of variance (Excel Microsoft). For significant differences, Po0.05 was considered statistically significant analysed by t-test. The data are presented as the mean7s.d.
Cellular mechanisms of neurobiology, immunology and human disease F de Nigris et al
